Novel targeting in acute myeloid leukaemia

Better understandings of gene mutations aid diagnostic tools in CLL

Eltrombopag helped reduce bleeding in children with immune thrombocytopenic purpura

Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL

Lenalidomide versus thalidomide in myeloma

Comment: Advances in haematological cancer presented at EHA 2014

Advances in chronic lymphocytic leukaemia: Expert panel discussion

Genetically modified T cells fight haematological cancer

Pivotal ruxolitinib data shows promise for patients with PV

Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL

Does the use of generics of imatinib for chronic myeloid leukaemia jeopardise patient safety?

Ibrutinib improves survival in CLL and SLL patients, RESONATE study shows